Success Metrics

Completion Rate
0%(0/1)
Active Trials
3(50%)
Terminated
1(17%)

Phase Distribution

Ph phase_3
1
17%
Ph phase_2
5
83%

Phase Distribution

0

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
5(83.3%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Terminated(1)
Other(2)

Detailed Status

Recruiting2
unknown2
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 25 (83.3%)
Phase 31 (16.7%)

Trials by Status

active_not_recruiting117%
recruiting233%
terminated117%
unknown233%

Recent Activity

3 active trials
Showing 5 of 6
recruitingphase_3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347
recruitingphase_2

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

NCT06890884
active_not_recruitingphase_2

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

NCT05406401
unknownphase_2

Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.

NCT04585152
unknownphase_2

Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma

NCT04246359
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06717347Phase 3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Recruiting
NCT06890884Phase 2

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Recruiting
NCT05406401Phase 2

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Active Not Recruiting
NCT04585152Phase 2

Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.

Unknown
NCT04246359Phase 2

Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma

Unknown
NCT04402580Phase 2

Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome

Terminated

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6